
Cognito Therapeutics Completes Enrollment in Alzheimer’s Neuromodulation Study
July 1, 2025 — Cognito Therapeutics announced the completion of enrollment in the HOPE pivotal trial evaluating its Spectris neuromodulation system for Alzheimer’s disease. The



